Evidence map›Paper›PMID 37463440›Full record

ReviewThe Journal of clinical investigation2023

The lung mesenchyme in development, regeneration, and fibrosis.

Elie El Agha, Victor J Thannickal

Open access · goldAbstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 53 citations in OpenAlex.

  1. Mapping Embryonic Mouse Lung Development Using Enhanced Spatial Transcriptomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Beyond the epithelium: multicellular niches in lung regeneration and disease.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Rediscovering Lung Lipofibroblast: A Lipid Wizard on the Alveolar Fibroblast Spectrum.American journal of respiratory cell and molecular biology · 2026
    Article
  14. Mechanobiology and Resolution of Lung Fibrosis.Annual review of physiology · 2026
    Review
  15. Article
  16. Article
  17. A Single Cell Atlas of the COPD Lung Identifies Inflammatory Reprogramming in Fibroblasts.International journal of chronic obstructive pulmonary disease · 2026
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Elie El AghaDepartment of Medicine V, Internal Medicine, Infectious Diseases and Infection Control, Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Justus-Liebig University Giessen, Giessen, Germany.
Victor J ThannickalJohn W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Justus-Liebig-Universität Gießen · DETulane University · US

Funding

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung DiseaseP01HL114470 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THANNICKAL, VICTOR J. · 2013 to 2022
$17.8M
AMPK in the Development and Resolution of Lung FibrosisR01HL139617 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Victor J. Thannickal, Jaroslaw Waldemar Zmijewski · 2019 to 2026
$4.4M
Metabolic Landscape of the Aging LungR01HL152246 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARNES, JARROD W., THANNICKAL, VICTOR J. · 2020 to 2023
$3.2M
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung FibrosisR01HL151702 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SANDERS, YAN, THANNICKAL, VICTOR J. · 2021 to 2025
$2.4M
Sirtuins in Lung Aging and FibrosisI01BX003056 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI THANNICKAL, VICTOR J. · 2016 to 2025
–
BLRD VA I01 BX003056NHLBI NIH HHS P01 HL114470NHLBI NIH HHS R01 HL139617NHLBI NIH HHS R01 HL151702NHLBI NIH HHS R01 HL152246
6 · The paper itself

Abstract

Mesenchymal cells are uniquely located at the interface between the epithelial lining and the stroma, allowing them to act as a signaling hub among diverse cellular compartments of the lung. During embryonic and postnatal lung development, mesenchyme-derived signals instruct epithelial budding, branching morphogenesis, and subsequent structural and functional maturation. Later during adult life, the mesenchyme plays divergent roles wherein its balanced activation promotes epithelial repair after injury while its aberrant activation can lead to pathological remodeling and fibrosis that are associated with multiple chronic pulmonary diseases, including bronchopulmonary dysplasia, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease. In this Review, we discuss the involvement of the lung mesenchyme in various morphogenic, neomorphogenic, and dysmorphogenic aspects of lung biology and health, with special emphasis on lung fibroblast subsets and smooth muscle cells, intercellular communication, and intrinsic mesenchymal mechanisms that drive such physiological and pathophysiological events throughout development, homeostasis, injury repair, regeneration, and aging.

Indexed as

LungPulmonary Disease, Chronic ObstructiveEpithelial CellsFibrosisHumansInfant, NewbornMesodermRegeneration

Identifiers

PMID37463440
PMCPMC10348757
OpenAlexW4384457728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.